DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company's primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:DARA
- CUSIP: N/A
- Web: www.darabiosciences.com/
- 50 Day Moving Avg: $0.87
- 200 Day Moving Avg: $0.87
- 52 Week Range: $0.67 - $1.05
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.93
- P/E Growth: 0.00
- Net Margins: -228.42%
- Return on Equity: -145.61%
- Return on Assets: -100.38%
- Average Volume: 85,603 shs.
Frequently Asked Questions for DARA Biosciences (NASDAQ:DARA)
What is DARA Biosciences' stock symbol?
DARA Biosciences trades on the NASDAQ under the ticker symbol "DARA."
How were DARA Biosciences' earnings last quarter?
DARA Biosciences Inc (NASDAQ:DARA) issued its quarterly earnings results on Monday, November, 2nd. The company reported ($0.14) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.14). The firm earned $1.18 million during the quarter, compared to the consensus estimate of $0.83 million. DARA Biosciences had a negative return on equity of 145.61% and a negative net margin of 228.42%. View DARA Biosciences' Earnings History.
Who are some of DARA Biosciences' key competitors?
Some companies that are related to DARA Biosciences include AbbVie (ABBV), ConvaTec Group PLC (CTEC), Mallinckrodt PLC (MNK), Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), Advanced Accelerator Applications S.A. (AAAP), Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Aimmune Therapeutics (AIMT), Eagle Pharmaceuticals (EGRX), Rockwell Medical (RMTI), Assembly Biosciences (ASMB), Novan (NOVN), Check Cap Ltd (CHEK), CorMedix (CRMD), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).
How do I buy DARA Biosciences stock?
Shares of DARA Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DARA Biosciences' stock price today?
MarketBeat Community Rating for DARA Biosciences (NASDAQ DARA)MarketBeat's community ratings are surveys of what our community members think about DARA Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of DARA Biosciences stock can currently be purchased for approximately $0.88.
Consensus Ratings for DARA Biosciences (NASDAQ:DARA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for DARA Biosciences (NASDAQ:DARA)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for DARA Biosciences (NASDAQ:DARA)Earnings History by Quarter for DARA Biosciences (NASDAQ DARA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/2/2015||Q3 2015||($0.14)||($0.14)||$0.83 million||$1.18 million||View||N/A|
|8/12/2015||Q215||($0.15)||($0.14)||$0.72 million||$0.99 million||View||Listen|
|5/13/2015||Q115||($0.12)||($0.16)||$0.75 million||$0.65 million||View||N/A|
|3/3/2015||Q4 2014||($0.11)||($0.04)||$0.75 million||$0.72 million||View||N/A|
|11/5/2014||Q3 2014||($0.13)||($0.11)||$0.55 million||$0.60 million||View||N/A|
|8/12/2014||Q114||($0.18)||($0.24)||$0.30 million||$0.41 million||View||N/A|
|5/12/2014||Q1 2014||($0.35)||($0.37)||$0.22 million||$0.16 million||View||N/A|
Earnings Estimates for DARA Biosciences (NASDAQ:DARA)
Current Year EPS Consensus Estimate: $-0.55 EPS
Next Year EPS Consensus Estimate: $-0.30 EPS
Dividend History for DARA Biosciences (NASDAQ:DARA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for DARA Biosciences (NASDAQ:DARA)Insider Trades by Quarter for DARA Biosciences (NASDAQ:DARA)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/3/2013||Christopher G Clement||President||Buy||14,000||$0.71||$9,940.00|| |
|5/30/2013||Haywood D Cochrane||Director||Buy||10,000||$0.70||$7,000.00|| |
|5/23/2013||Timothy James Heady||Director||Buy||10,000||$0.75||$7,500.00|| |
|5/17/2013||David Drutz||CEO||Buy||25,000||$0.70||$17,500.00|| |
|9/17/2012||David Drutz||CEO||Buy||25,000||$1.06||$26,500.00|| |
|9/11/2012||Haywood D Cochrane||Director||Buy||5,000||$0.80||$4,000.00|| |
Headline Trends for DARA Biosciences (NASDAQ:DARA)
Latest Headlines for DARA Biosciences (NASDAQ:DARA)
|Scientists Take New Approach to Fighting Type 1 Diabetes|
www.wsj.com - June 25 at 3:02 AM
|Repligen (RGEN) & DARA Biosciences (DARA) Head to Head Review|
www.americanbankingnews.com - June 10 at 10:10 AM
|Will microbes save agriculture? - Los Angeles Times|
www.latimes.com - May 28 at 4:06 PM
|Will Midatech Pharma plc be the next Shire plc? - Motley Fool UK|
www.fool.co.uk - May 4 at 4:08 PM
|Midatech Loss Widens On Acquisition Costs, But Revenue Surges - London South East (registration) (blog)|
www.lse.co.uk - April 13 at 4:14 PM
|Midatech Loss Widens On Acquisition Costs, But Revenue Surges|
www.morningstar.co.uk - April 13 at 4:14 PM
|DARA BIOSCIENCES, INC. Financials|
finance.yahoo.com - December 8 at 1:16 PM
|MIDATECH PHARMA US INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting o|
biz.yahoo.com - December 4 at 5:07 PM
|DARA BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events, Financi|
biz.yahoo.com - December 2 at 4:32 PM
|DARA BIOSCIENCES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stan|
biz.yahoo.com - November 18 at 4:31 PM
|DARA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex|
biz.yahoo.com - November 2 at 4:36 PM
|Edited Transcript of DARA earnings conference call or presentation 13-Aug-15 1:00pm GMT|
finance.yahoo.com - October 19 at 1:19 PM
|DARA BioSciences to Present at the 2015 Aegis Growth Conference on October 8, 2015|
finance.yahoo.com - October 6 at 8:00 AM
|DARA BioSciences Announces U.S. Launch of Oravig(R) (miconazole), the First and Only Orally-Dissolving Buccal Tablet Available for Treatment of Adults With Oral Thrush|
finance.yahoo.com - October 5 at 8:00 AM
|DARA BioSciences to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015|
finance.yahoo.com - September 23 at 4:30 PM
|DARA BioSciences to Present at the 17th Annual Rodman and Renshaw Global Investment Conference on September 9, 2015|
finance.yahoo.com - September 2 at 4:30 PM
DARA Biosciences (DARA) Chart for Thursday, July, 27, 2017